Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
oleh: Evangelos Terpos, Ioannis V. Kostopoulos, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Pantelis Rousakis, Alexandra T. Argyriou, Nikolaos Kanellias, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Dimitrios C. Ziogas, Aristea-Maria Papanota, Marilyn Spyropoulou-Vlachou, Ioannis P. Trougakos, Ourania E. Tsitsilonis, Bruno Paiva, Meletios A. Dimopoulos
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2019-12-01 |
Deskripsi
Abstract. Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6.